Home

Rx-to-OTC Switch Data

Rx-to-OTC Switch Management Issues

Rx-to-OTC Switch Trends

SWITCH® Indexes

Where to find more information on Rx-to-OTC Switches 
 

 
SWITCH 1998 Index 
 
Date
Vol.
No.
Switch Forecast
 Switch Scene
Dec '97/
Jan'98
4
6
 PREDICTION: The Inevitable Major Growth of Dual Regulatory Status - Structural Change in US Rx & OTC Market Provides Problems and Opportunities P&G/Astra Merck Omeprazole Deal & Strategy Typical Format for the Future A Summary of 1997 Events from Our SWITCHÒ Network (Major newsworthy stories not covered in detail by SWITCHÒ this year) 
SPECIAL REPORT: All the Switches of 1997 in Major Markets. Including Expected Switch Molecules and Pending Switch Issues.
SWITCHÒ 1998 Index
Feb '98
4
7
 The Inevitable Switch and Dual Status of Non-Sedating Antihistamines in the US - Breathtaking Changes in the Expanding US Allergy Market Opportunities Still Abundant If You Do Your Homework Time and Resources - The Enemies Against Engineering Switch Success Through Product Differentiation - It's About Having Enough Time and Money, Basically. 
SPECIAL REPORT: 10 Events That Shook the Allergy World in the Last 20 Months
Mar '98
4
8
 PART ONE - Prevention of Serious Osteoporosis Likely To Be A New OTC Indication — The Drugs Are Safe, The Treatment Self-Monitorable — FDA Muddies the Water After "Mis-Speaking" on Hypercholesterolemia SWITCHÒ Notables - Unusual Rx-to-OTC Switch Stories - From Around Our SWITCHÒ Network That May Have Escaped Your Attention 
SPECIAL REPORT: Assessing OTCness of Switch Candidates for Chronic and/or Recurrent Illness
Apr '98
4
9
 PART TWO - Prevention of Serious Osteoporosis Likely To Be A New OTC Indication - Improved New Rx Entries Threaten Premarin and Fosamax. Is a Switch Next? Will FDA "Mis-Speaking" on Hypercholesterolemia Affect Osteoporosis OTC Chances? Japan and the United Kingdom: Resale Price Maintenance and Distribution Changes. 
SPECIAL REPORT: A Comparison of the Situations Surrounding the Possible Indication Switch of Hypercholesterolemia and Osteoporosis
May '98
4
10
 The Good News: Finally Ministry of Health Progress Justifies Inclusion of Mexico as a Major OTC World Market. The Bad News: Huge Under the Counter (UTC) Market Remains. Question: Who Leads Now in the Number of Ingredients Switched - the US or Mexico? Immediate Dual Status Should Be Granted to Nicotine Inhalation Products-Currently Illogical Regulatory Rules Favor Tabacco Companies Over Nicotine Addiction Alternatives-The Result is Unnecessary Loss of Life and High Medical Expenses. 
SPECIAL REPORT: 31 New Switches in Mexico. 
Country Update: Canada and France
Jun/
Jul '98
5
1
 SPECIAL ISSUE: 
FOURTH ANNIVERSARY OF SWITCHÒ 
GLOBAL REVIEW: Review of Five Global Rx-to-OTC Trends - Sources of Future Volume Are Changing - Rx R&D Increases Control Over Much of OTC Destiny		 SPECIAL REPORT: All the Major 1998 Switches to Date. 
Publisher's Letter: A Progress Report to our SWITCHÒ Readers
Aug '98
5
2
 SWITCHÒ -- Winner of APEX'98 Awards for Publication Excellence
The Future OTC Cholesterol Indication: "For the Prevention of Heart Attacks" - Prevention Not Treatment, Statins Not Resins, and Proper Target Audience Is the Way to Go — Rx-to-OTC Switch Process Gains Speed and Is Definitely Not Concluded		 The "OTCability" of the Emergency Contraception Indication — Legal & Cultural Factors Scare Pharma, Restrict Access — "Prescribing Protocol" Solution (?) Is Like Being "Half-Pregnant". 
SPECIAL REPORT: Lipid Regulating Agents and their Performance
Sept '98
5
3
 PART ONE: Is There a Successful Strategic Defense Against Rx and OTC Generics? Currently, the Number of ANDA's Is Growing Fast (+23%) -- Dual Status Is the Best Alternative Japan OTC: Suppressed Stepchild of the Rx Market - High Expectations on the H2 Switch Opportunity Dashed - Did the Pharmacists' Errors Set Back OTC Evolution in Japan? SPECIAL REPORT: The Next Three Years (and US $6.8 billion) of Patent Expirations in the US.
Oct '98
5
4
 PART TWO: Is There a Successful Strategic Defense Against Rx and OTC Generics? Best Rx and OTC Generics Defense: Extended Patent Protection and/or Dual Status - Sepracor's ICEÔ Strategy Dampens Generics Fire FOLLOW-UP: 
Australia: Finally Approves S3 Consumer Advertising for 12 OTC Substances - A Small But Important Step
US: Rx Products for Emergency Contraception Finally Approved - Rx-to-OTC Switch May Follow Soon Despite "Cultural" Issues
US & UK: Drug Chains Make OTC Osteoporosis Test Broadly Available - The Rx-to-OTC Switch of the Indication Should Follow. 
Country Summary: France, Canada & The UK
Nov '98
5
5
 PART THREE: Is There a Successful Strategic Defense Against Rx and OTC Generics? What is the Difference Between the Rx Generic Defense and Dual Status? Today's "Therapeutic Density" Demands More Product Options, Lower Rx Sales Forecasts Lifestyle Drugs: How Much is "Lifestyle" Improvement Worth? With a Demanding Public Questionable "OTCability" May Be A Blessing for the Industry. 
SPECIAL REPORT: Key Strategic Differences Between a Generic Defense and Dual Status.
Country Update: Canada & The UK
 
 

For further information on subscribing to SWITCH(r). 

Return to the Top 
 

Francesco International Tel 1-973-761-5566, Fax 1-973-761-6996, Email Franint